The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Sign Up to like & getrecommendations! Published in 2017 at "Nature"
DOI: 10.1038/nature21702
Abstract: Chronic myeloid leukaemia (CML) is driven by the activity of the BCR–ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of patients treated with imatinib surviving… read more here.
Keywords: inhibitor; abl1; kinase; bcr abl1 ... See more keywords
An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2019.1623666
Abstract: Since the introduction of imatinib ‘the first tyrosine kinase inhibitor (TKI)’ that targets BCR-ABL1, chronic myeloid leukemia (CML) has become a controlled malignancy at which patients with optimal responses would expect similar life expectancies of… read more here.
Keywords: abl1; treatment; kinase inhibitor; bcr abl1 ... See more keywords
Expanding the clinical and mutational spectrum of germline ABL1 mutations-associated syndrome
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014782
Abstract: Rationale: Clinical and genetic management of patients with rare syndromes is often a difficult, confusing, and slow task. Patient concerns: Male child patient with a multisystemic disease showing congenital heart defects, facial dysmorphism, skeletal malformations,… read more here.
Keywords: abl1 mutations; associated syndrome; abl1; germline abl1 ... See more keywords
Allosteric Plus Catalytic BCR-ABL1 Inhibitors Promote Durable Responses.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2017-062
Abstract: A selective allosteric ABL1 kinase inhibitor suppresses the growth of BCR-ABL1-driven CML. read more here.
Keywords: catalytic bcr; abl1; plus catalytic; allosteric plus ... See more keywords
The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113029
Abstract: Background TKI discontinuation is now a critical goal of CML management and several studies have demonstrated the feasibility of stopping safely imatinib (IM). A sustained deep molecular response (DMR) on long-term TKI therapy seems critical… read more here.
Keywords: cml patients; ddpcr; abl1; duration ... See more keywords
A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-120029
Abstract: Dasatinib with corticosteroid yields high complete remission (CR) rates in Ph+ ALL with minimal induction death. Optimal post-remission therapy is not known. We report a prospective study evaluating dasatinib/dexamethasone induction then consolidation with reduced-intensity conditioning… read more here.
Keywords: research; abl1; course; research funding ... See more keywords
Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131781
Abstract: BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph+) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1T315I-mutant disease. However, for those patients who acquire BCR-ABL1 compound… read more here.
Keywords: research; abl1; board; research funding ... See more keywords
Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-140968
Abstract: Tyrosine kinase inhibitors (TKIs) that inhibit the transphosphorylation activity of the BCR-ABL1 oncoprotein by binding the ATP-binding site of the catalytic domain of protein kinases are well established as being effective drugs for the treatments… read more here.
Keywords: abl1; kinase; current employment; pocket ... See more keywords
SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006076
Abstract: Key Points SFPQ-ABL1 is localized to the nuclear compartment and is a relatively weaker driver of cellular proliferation compared with BCR-ABL1. SFPQ-ABL1 and BCR-ABL1 activate distinct signaling networks, both of which converge on inhibiting apoptosis… read more here.
Keywords: signaling networks; abl1 bcr; bcr abl1; sfpq abl1 ... See more keywords
Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform
Sign Up to like & getrecommendations! Published in 2019 at "AntiCancer Research"
DOI: 10.21873/anticanres.13918
Abstract: Background/Aim: The Philadelphia chromosome is the most frequent cytogenetic abnormality in chronic myelogenous (CML). More than 95% of CML patients are diagnosed with the e13a2 or e14a2 BCR-ABL1 fusion transcripts while, in about 1% of… read more here.
Keywords: cml; abl1; abl1 fusion; e12a2 ... See more keywords